Subscribe to our Email Alerts

Investor Fact Sheet

Company Name: Amplia Therapeutics Limited (ACN 165 160 841)

Business Description:

Amplia Therapeutics Limited (ASX: ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic cancer. FAK also plays a significant role in a number of fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF).

Shares on Issue: 194,005,536 Fully Paid Ordinary Shares
Options on Issue:

25,439,421 ATXO Listed Options - Ex Price $0.28, Expiry 31 December 2023

7,377,165 Unlisted Options (at varying exercise prices and expiry dates)


Target Market Determination:
ATXO Options

The Company has made a Target Market Determination in respect of ATXO Listed Options - Ex Price $0.28, Expiry 31 December 2023 which can be viewed here.

Market Listings:

Australian Securities Exchange (ASX Code: ATX)


Dr Warwick Tong, Chairman, Non-Executive Director
Dr Chris Burns, CEO and Managing Director
Dr Robert Peach, Independent Non-Executive Director
Ms Jane Bell, Independent Non-Executive Director


Dr Chris Burns, CEO and Managing Director
Mr Tim Luscombe, Chief Financial Officer
Dr Rhiannon Jones, Chief Operating Officer
Mr Andrew Cooke, Company Secretary

Registered Office:

Level 17
350 Queen Street
Melbourne VIC 3000


Grant Thornton Audit Pty
GPO Box 4736
Melbourne 3001